PMID- 24614127
OWN - NLM
STAT- MEDLINE
DCOM- 20160229
LR  - 20211021
IS  - 1536-4801 (Electronic)
IS  - 0277-2116 (Print)
IS  - 0277-2116 (Linking)
VI  - 59
IP  - 1
DP  - 2014 Jul
TI  - Pentavalent rotavirus vaccine in infants with surgical gastrointestinal disease.
PG  - 44-8
LID - 10.1097/MPG.0000000000000361 [doi]
AB  - OBJECTIVES: Pentavalent rotavirus vaccine (RV5) has been shown to be 
      well-tolerated and efficacious in preventing rotavirus gastroenteritis in healthy 
      infants. Safety and immunogenicity of RV5 in infants with surgical 
      gastrointestinal disease have not been studied. The aim of the present study was 
      to evaluate the safety and immunogenicity of RV5 in infants with a history of 
      congenital or acquired intestinal disease requiring resection compared with 
      healthy infants. METHODS: Infants with intestinal resection were matched by 
      gestational age and chronological age to healthy infants (controls). Dose 1 of 
      RV5 was given at 10 to 12 weeks of chronological age. Doses 2 and 3 were given at 
      intervals of 4 to 10 weeks, with all 3 doses given by 32 weeks. All infants were 
      monitored for adverse events (AEs) by telephone calls, clinic visits, and 
      parental written reports during the first 42 days after each dose and monthly 
      thereafter by telephone for 12 months. Serum anti-rotavirus immunoglobulin A 
      (IgA) titers were measured prevaccination and 2 weeks after dose 3. RESULTS: A 
      total of 5 infants with surgical gastrointestinal disease and 3 control subjects 
      were enrolled. All participants (100%) mounted a 3-fold increase in serum 
      anti-rotavirus IgA geometric mean titer postvaccination. RV5 administration to 
      surgical infants was well tolerated with a majority of AEs being attributed to 
      the underlying medical condition. CONCLUSIONS: Postvaccination serum 
      anti-rotavirus IgA levels indicate that RV5 is immunogenic in infants with a 
      history of bowel resection, despite varying lengths of residual bowel. RV5 was 
      well tolerated with few vaccine-related AEs.
FAU - McGrath, Eric J
AU  - McGrath EJ
AD  - *Carman and Ann Adams Department of Pediatrics, Wayne State University School of 
      Medicine daggerDivision of Gastroenterology, Hepatology and Nutrition, Boston 
      Children's Hospital, Boston, MA.
FAU - Thomas, Ron
AU  - Thomas R
FAU - Duggan, Christopher
AU  - Duggan C
FAU - Asmar, Basim I
AU  - Asmar BI
LA  - eng
GR  - K24 HD058795/HD/NICHD NIH HHS/United States
GR  - K24HD058795/HD/NICHD NIH HHS/United States
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pediatr Gastroenterol Nutr
JT  - Journal of pediatric gastroenterology and nutrition
JID - 8211545
RN  - 0 (Antibodies, Viral)
RN  - 0 (Immunoglobulin A)
RN  - 0 (RotaTeq)
RN  - 0 (Rotavirus Vaccines)
RN  - 0 (Vaccines, Attenuated)
SB  - IM
MH  - Antibodies, Viral/*blood
MH  - Case-Control Studies
MH  - Female
MH  - Gastroenteritis/*virology
MH  - Humans
MH  - Immunization Schedule
MH  - Immunoglobulin A/blood
MH  - Infant
MH  - Intestinal Diseases/surgery
MH  - Male
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Rotavirus/*immunology
MH  - Rotavirus Infections/*immunology
MH  - Rotavirus Vaccines/administration & dosage/*adverse effects/*immunology
MH  - Vaccines, Attenuated/administration & dosage/adverse effects/immunology
PMC - PMC4624282
MID - NIHMS731690
COIS- The other authors report no conflicts of interest.
EDAT- 2014/03/13 06:00
MHDA- 2016/03/02 06:00
PMCR- 2015/10/28
CRDT- 2014/03/12 06:00
PHST- 2014/03/12 06:00 [entrez]
PHST- 2014/03/13 06:00 [pubmed]
PHST- 2016/03/02 06:00 [medline]
PHST- 2015/10/28 00:00 [pmc-release]
AID - 10.1097/MPG.0000000000000361 [doi]
PST - ppublish
SO  - J Pediatr Gastroenterol Nutr. 2014 Jul;59(1):44-8. doi: 
      10.1097/MPG.0000000000000361.